Sarah Cannon Research Institute

Northwest Bio collaborates with U.K. cancer institutions for DCVaxR-Direct trial

Wednesday, November 7, 2012 11:51 AM

Northwest Biotherapeutics, a Bethesda, Md.-based biotechnology company developing DCVax personalized immune therapies for cancer, has initiated a collaboration with U.K.-based cancer institutions Sarah Cannon Research U.K. and Leaders in Oncology Care (LOC) on a phase I/II trial with DCVax-Direct for metastatic colon cancer. 

More... »

Marshall Edwards initiates phase I ME-143 trial

Friday, September 9, 2011 12:48 PM

Marshall Edwards, an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, has initiated a phase I clinical trial of its lead drug candidate ME-143 in patients with refractory solid tumors. The trial is being conducted in collaboration with the Sarah Cannon Research Institute in Nashville, Tennessee, following the approval of an Investigational New Drug (IND) application by the FDA last month.

More... »

Sarah Cannon Research Institute names new CFO, CIO

Tuesday, March 22, 2011 12:02 PM

Sarah Cannon Research Institute (SCRI), based in Nashville, Tenn., has named Ajay Gupta chief financial officer and Andy Corts chief information officer.

More... »

Sarah Cannon Names New CFO

Friday, March 19, 2010 07:05 AM

Strategic research organization Sarah Cannon Research Institute (SCRI) appointed Dean Ferrigno as chief financial officer (CFO), replacing Phil Cestaro, who is now president, SCRI Services. SCRI Services specializes in clinical trial administration with a focus on oncology drug development programs. Cestaro, who joined the company in 2006, will continue to be SCRI’s chief information officer in addition to the new position.

More... »

University of Oklahoma, Sarah Cannon Partner on Early-Stage Cancer Research

Monday, March 8, 2010 06:43 AM

The University of Oklahoma’s OU Cancer Institute (OUCI) is partnering with strategic research organization Sarah Cannon Research Institute (SCRI) to expand the school’s early-phase oncology clinical trials program.

More... »